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Depression  and  anxiety  play  an important  role  in  decreasing  quality  of life  worldwide.  Since  trypto-
phan  is  a serotonin  precursor  and  low  levels  of  serotonin  seems  to be  related  to  depression,  the  effect
of  oral  tryptophan  has  been  investigated  for possible  potentiation  of  the action  of antidepressant  drugs.
We  investigated  the  effects  of  chronically  administered  tryptophan  (50 mg/kg/day,  p.o.)  with  or  without
concomitant  ﬂuoxetine  (10 mg/kg/day,  s.c.)  on  adult  rats  regarding  depression-related  and  anxiety-like
behaviors.  Tryptophan  levels  in  cerebrospinal  ﬂuid  (CSF)  were  measured  4 h  after  a single  administrationluoxetine
epression
orced swimming test
nxiety
levated  plus-maze
of  daily  dosages  of  chronic  treatments.  We  found  that  tryptophan  increased  depressive-related  behavior,
but  did  not  alter  anxiety-like  behavior.  However,  ﬂuoxetine  decreased  depression-related  behavior  and
was  anxiogenic.  Tryptophan  with  concomitant  ﬂuoxetine  did  not  alter  anxiety-like  behavior.  Moreover,
our  data  suggests  that the  antidepressant  effect  of ﬂuoxetine  was  not  enhanced  by  concomitant  admin-
istration  of  tryptophan,  which  could  be  associated  with  increased  levels  of  tryptophan  in  CSF.  Further
investigations  are  needed  to elucidate  the  related  mechanisms.erotonin (5-HT) has been shown to play a crucial role not only in
hysiological processes, but in the mood and behavior too [15].
ymptoms of depression, panic, aggression and suicidality have
een associated with low levels of 5-HT and suicide behavior sec-
ndary to depressive disorder seem to be associated with elevated
xpression of neuronal tryptophan hydroxylase 2 (TPH2) as well
s changes in brain serotonin turnover [1]. Due to these facts, the
tudy of the psychopathology of mood disorders has focused on
erotonergic system as target for new therapies.
The biosynthesis of the monoamine 5-HT starts with the
ssential amino acid tryptophan, which is metabolized to 5-
ydroxytryptophan (5-HTP) by tryptophan hydroxylase (TPH,
eing the TPH2 the central isoform, speciﬁcally expressed in the
rain and the TPH1 the peripheral isoform [30]) in an initial, rate-
imiting step; 5-HTP is then further decarboxylated to 5-HT by
romatic amino acid decarboxylase. Despite the initial and rate-
Abbreviations: CSF, cerebrospinal ﬂuid; EPM, elevated plus-maze; FST, forced
wimming  test; p.o., per oral; SSRI, selective serotonin reuptake inhibitor;
-HT,  serotonin; s.c., subcutaneously; TPH, tryptophan hydroxylase; 5-HTP, 5-
ydroxytryptophan; 5HIAA, 5-hydroxyindole-acetic acid.
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limiting step of the serotonin synthesis being the hydroxylation by
TPH2 in the brain, the serotonin level is a product of both synthesis
and degradation.
It  has been proved low dietary tryptophan seems to have an
anxiogenic and depressant effect on rat behavior [33], while acute
depletion in adult rats seems to enhance the emotional responsive-
ness to stress situations [29]. Oral administration of tryptophan has
been shown to increase serotonin synthesis and metabolism in dif-
ferent brain regions in rats [11,14] and improve cognitive functions
[14]. In this regard, tryptophan has potential therapeutic effect in
an attempt to increase levels of serotonin and its precursors in the
brain of subject affected by anxiety or mood disorders.
Fluoxetine, has been applied in the treatment of depression
among human with different ages and, more recently, this drug
was also recommended for the treatment of anxiety [18]. The
antidepressant effect of ﬂuoxetine in rats submitted to the forced
swimming test (FST) has ever been established [16,20].
Few  data exist about chronic effects of tryptophan and inter-
action with selective serotonin reuptake inhibitors (SSRIs), hence
we investigate the effects of a 48-days treatment of oral trypto-
Open access under the Elsevier OA license.phan with or without concomitant ﬂuoxetine in adult rats. Animal
behavior during the FST and the elevated plus-maze (EPM) was
analyzed in order to assess whether the administration of tryp-
tophan as a dietary supplement may  be useful in enhancing the
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uoxetine effects regarding depression-related and/or anxiety-like
ehaviors.
Sixty-seven male Wistar rats (60 days old, weighting
30–280 g), which were obtained from our own breeding colony
University of Passo Fundo), were used. Animals were kept in
emperature-regulated room (22 ± 1 ◦C), on a 12 h light/ 12 h
ark cycle, four per cage, with food and water ad libitum and air
elative humidity was kept at 55 ± 5%. Our institutional protocols
or experiments with animals (“Guidelines for Animal Care”),
esigned to avoid suffering and limit the number of animals used,
ere followed throughout. The methodology of this study was in
trict accordance with the ethical principles in animal experiments
f the Brazilian College of Animal Experimentation and with the
ational Institutes of Health Guide for Care and Use of Laboratory
nimals.
Animals used to behavioral tests: Thirty-three male Wistar rats
ere treated once a day with saline (NaCl 0.9%, 5 mL/kg p.o.)
r l-tryptophan (50 mg/kg, 5 mL/kg p.o., Sigma, USA) [14] with
oncomitant administration of saline (NaCl 0.9%, 1 mL/kg s.c.) or
uoxetine (10 mg/kg, 1 mL/kg s.c., Sigma, USA) [16] for 48 days,
erforming the following groups: control group – saline (s.c. and
.o.); l-tryptophan group – saline s.c. and l-tryptophan p.o.; ﬂuox-
tine group – saline p.o. and ﬂuoxetine s.c.; experimental group –
-tryptophan p.o. and ﬂuoxetine s.c. In this study, ﬂuoxetine was
sed as a negative control for depression-related behavior.
Animals used to CSF tryptophan measurement: Thirty-six male
istar rats were treated with a single administration of daily
osages of chronic treatments described above.
The behavioral tests were performed 4 h after the daily admin-
stration of drugs and the animals had a habituation period of 2 h
t the local test.
The modiﬁed FST [5,6] was conducted at 42 days of treatment.
he rats were placed individually in a tank (73 cm diameter, 56 cm
eight, ﬁlled for a depth of 30 cm with water and kept at 25 ◦C).
he rats were removed after 15 min, dried, and returned to their
age. Twenty-four hours after, the rats were replaced in the swim
ank (under the same conditions) for 5 min, and the analysis of time
pent in immobility, swimming or climbing behaviors was made,
uantiﬁed with aid of digital chronometers.
The EPM test was made 4 days after the forced-swimming
est. The maze was made of plexiglas, having 2 closed arms
50 cm length, 10 cm width) with transparent walls, and 2 open
rms of equal length and width, forming a square cross with a
0 cm × 10 cm center piece. The distance from the ﬂoor was  of
3 cm.  The environment was silent and dimly lit (no light directly
ocused the apparatus). Animals were placed individually in the
enter of the maze, in junction between open and closed arms, fac-
ng one of the open arms, and observed for 5 min, evaluating the
ime spent in open, closed arms and center of the maze and open,
nd closed entries [21].
Animals used for sampling CSF were treated as speciﬁed above,
ith a single administration at the same time of day that chronic
reatment was made. Four hours after administration, rats were
nesthetized with ketamine (80 mg/kg, Vetbrands, Brazil) and
ylazine (10 mg/kg, Coopers Brasil Ltda., Brazil) i.p., placed in a
tereotaxic apparatus, and CSF samples (40–60 L per rat) were
rawn by direct puncture of the cisterna magna with an insulin
yringe (27 gauge × 1/2 in. length) [4].  In order to obtain cell-
ree supernatants, all samples were centrifuged at 10,000 × g in
n eppendorf centrifuge during 5 min  and samples stored (−70 ◦C)
ntil tryptophan quantiﬁcation by high-performance liquid chro-
atography (HPLC).
HPLC was performed with CSF cell-free supernatant aliquots
o quantify tryptophan levels [13]. Brieﬂy, samples were deriva-
ized with o-phthalaldehyde and separation was  carried out
ith a reverse phase column (Supelcosil LC-18, 250 mm × 4.6 mm,etters 499 (2011) 59– 63
Supelco) in a Shimadzu Instruments liquid chromatograph (50 L
loop valve injection). The mobile phase ﬂowed at a rate of
1.4 mL/min and column temperature was 24 ◦C. Buffer composi-
tion is A: 0.04 mol/L sodium dihydrogen phosphate monohydrate
buffer, pH 5.5, containing 20% of methanol; B: 0.01 mol/L sodium
dihydrogen phosphate monohydrate buffer, pH 5.5, containing
80% of methanol. The gradient proﬁle was modiﬁed according
to the content of buffer B in the mobile phase: 0% at 0.00 min,
25% at 13.75 min, 100% at 15.00–20.00 min, 0% at 20.01–25.00 min.
Absorbance was read at 360 nm and 455 nm,  excitation and emis-
sion respectively, in a Shimadzu ﬂuorescence detector. Samples of
50 L were used and concentration was expressed in M.
Data were expressed as mean ± standard error mean (S.E.M.)
and analyzed by two-way ANOVA followed by simple main effects
test if interaction was positive. Independent samples T-test was
used for comparing experimental × control groups for parameters
without signiﬁcant interaction between treatments. For all analy-
ses, p < 0.05 was considered signiﬁcant.
Two-way ANOVA was  conducted for examining the effect of
ﬂuoxetine and tryptophan on parameters of FST and EPM. There
was no signiﬁcant interaction between the treatments in any of
the experimental parameters. Independent samples T-test did not
found difference between experimental and control group for any
behavioral parameter, except climbing at FST (T = 3.119, p = 0.007).
Immobility: Isolated effects were found for ﬂuoxetine
[F(1,29) = 4.942, p = 0.034] and tryptophan [F(1,29) = 15.723,
p < 0.001], reducing and increasing the time spent in immobility
behavior, respectively (Fig. 1A).
Swimming: Isolated effects were found for ﬂuoxetine
[F(1,29) = 6.113, p = 0.02], which increased the time of swim-
ming behavior. In addition, tryptophan showed a tendency to
decrease time of swimming [F(1,29) = 4.012, p = 0.055] (Fig. 1B).
Climbing: Tryptophan showed an isolated effect diminishing the
time of climbing behavior [F(1,29) = 9.185, p = 0.005]. Fluoxetine did
not have effect at this parameter (Fig. 1C).
Open arms: Fluoxetine decreased the time spent in open arms
[F(1,29) = 20.941, p < 0.001]. Tryptophan had no effect for this
parameter (Fig. 2A).
Closed arms: Fluoxetine increased the time spent in closed arms
[F(1,29) = 12.754, p = 0.001]. Tryptophan showed no effect for this
parameter (Fig. 2B).
Center area: Fluoxetine increased time spent in the center area
[F(1,29) = 9.587, p = 0.004]. Tryptophan showed no effect for this
parameter (Fig. 2C).
Ratio of entries (open arms vs. total): Fluoxetine had an iso-
lated effect which decreased the ratio of entries [F(1,29) = 10.722,
p < 0.01]. Tryptophan did not affect the ratio of entries (Fig. 3).
Two-way ANOVA was  conducted for examining the effect of
acute (a single dose) tryptophan and ﬂuoxetine administration on
CSF tryptophan levels. There was  a signiﬁcant interaction between
the effects of these compounds [F(1,30) = 4.309, p = 0.047] and a
signiﬁcant isolated effect for ﬂuoxetine [F(1,30) = 12.614, p < 0.001].
Simple main effects analysis showed that ﬂuoxetine promoted
an increase (approximately 20%) in CSF tryptophan levels after 4 h
of subcutaneous ﬂuoxetine administration with concomitant tryp-
tophan [F(1,30) = 14.844, p < 0.01] but not with saline administrated
orally [F(1,30) = 1.167, p > 0.05] (Fig. 4).
We investigated the hypothesis of potentiation of the effect of
ﬂuoxetine by tryptophan on depression-related and anxiety-like
behavior. It was hypothesized that administration of tryptophan
would affect mood and behavior due to an effect over serotonin-
ergic system – resulting from a possible increase in brain 5-HT
levels.
According to our data, oral tryptophan administration increased
depression-related behavior assessed by the FST, showing
increased immobility time, decreased climbing and showing a ten-
F. Hansen et al. / Neuroscience Letters 499 (2011) 59– 63 61
Fig. 1. Effect of chronic oral tryptophan administration and/or ﬂuoxetine (s.c.) on
immobility (A), swimming (B), and climbing (C) in the FST. The data are expressed
as  mean ± S.E.M. (n = 8 per group, except the experimental group n = 9). Results of
two-way ANOVA (ﬂuoxetine × tryptophan) are given within the graphs. Signiﬁcant
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Fig. 2. Effect of chronic oral tryptophan administration and/or ﬂuoxetine (s.c.) on
the  time seconds spent in open arms (A), closed arms (B), and center area (C) of the
[8,22].
It is known that the onset of the therapeutic effects of all SSRIs
requires drug administration for several weeks or even months [19]
Fig. 3. Effect of chronic oral tryptophan administration and/or ﬂuoxetine (s.c.) onp < 0.05) factors are in bold. *p = 0.007 (independent samples T-test comparing con-
rol × experimental group).
ency to decrease swimming behavior. Fluoxetine alone decreased
epression-related behavior, since it decreased the immobility
ehavior and increased the swimming time (Fig. 1). In the EPM,
ryptophan did not alter the anxiety-like behavior, while that ﬂu-
xetine demonstrated an anxiogenic effect (Figs. 2 and 3).
Our data suggests that the concomitant administration of tryp-
ophan and ﬂuoxetine does not improve the effect of ﬂuoxetine
ecreasing depressive-related behavior. There was  a trend of inter-
ction between tryptophan and ﬂuoxetine in immobility behavior
Fig. 1A), which might suggest some loss of ﬂuoxetine effect and
ould be associated with increased levels of tryptophan in CSF
Fig. 4). We  also observed that concomitant administration did not
lter anxiety-like behaviors (Figs. 2 and 3).
The results found with ﬂuoxetine decreasing depression-related
ehavior and its anxiogenic effect, are in accordance with pre-
iously studies, even with different routes of administration
20,26,31]. It has been purposed that existence of some contro-
ersial effects of ﬂuoxetine on anxiety-like behavior are due to
ifferent posologies [7,9]. However, studies regarding acute ﬂu-
xetine administration with different routes and doses (between
0 and 30 mg/kg) found, in the majority of cases, an increase in
xtracellular brain 5-HT levels [2] and it has been shown that
ubcutaneous administration of ﬂuoxetine increases extracellularEPM. The data are expressed as mean ± S.E.M. (n = 8 per group, except the experi-
mental group n = 9). Results of two-way ANOVA (ﬂuoxetine × tryptophan) are given
within the graphs. Signiﬁcant (p < 0.05) factors are in bold.
levels of 5-HT in brain similarly to intraperitoneal administrationthe  number of entries in EPM. Data are shown as ratio of entries (open arms vs. total).
The data are expressed as mean ± S.E.M. (n = 8 per group, except for the experimental
group n = 9). Results of two-way ANOVA (ﬂuoxetine × tryptophan) are given within
the  graphs. Signiﬁcant (p < 0.05) factors are in bold.
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Fig. 4. Effect of single tryptophan administration (p.o.) and/or ﬂuoxetine (s.c.) on
CSF  levels of tryptophan 4 h after drugs administration. The data are expressed as
mean ± S.E.M. (n = 9 per group, except for the tryptophan group n = 7). Results of
two-way ANOVA (ﬂuoxetine × tryptophan) are given within the graphs. Signiﬁcant
(p < 0.05) factors are in bold. *Simple main effects test showed CSF tryptophan levels
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[18] L.T. Nash, S. Hack, The pharmacological treatment of anxiety disorders in chil-ave increased for ﬂuoxetine administration with concomitant tryptophan (p < 0.01)
ut not with saline administrated orally.
lthough many studies investigate the effects of ﬂuoxetine treat-
ent and its mechanism of action under acute treatments [8,12,22].
Controversial data have emerged demonstrating an inabil-
ty of tryptophan intervention in slowing depression in humans
24]. Studies with animal model demonstrated that the combi-
ation of tryptophan with ﬂuoxetine, zimelidine, clomipramine,
nd amitryptyline has only occasionally achieved any potentiation
r acceleration of the clinical effect [32]. However, pretreatment
ith tryptophan conferred citalopram response in the FST in two
therwise citalopram-insensitive mouse strains [3] and 5-HTP
dministration after ﬂuoxetine treatment increased 5-HT levels [8].
Studies with tryptophan restriction showed increased in immo-
ility behavior of rats under FST. This depressive behavior could
e related to decrease of serotoninergic activity [16,33]. However,
ur data suggests that oral tryptophan seems not to have effect in
 context without dietary restrictions or depletion of 5-HT in the
rain.
In experimental group, the increased availability of tryptophan
o the brain would not be necessary due to the action of ﬂuox-
tine. Moreover, it is known that excessive tryptophan may lead
o deletery effects on brain, such as convulsions and apoptosis
27] and oral administration of tryptophan produces a consequent
ncrease in tryptophan in plasma and blood [10,11], thus this amino
cid may  be directed to other metabolic pathways [23]. About 1%
f dietary tryptophan is converted to 5-HT [23] and oral admin-
stration of tryptophan in humans causes an increase of 5-HT
nd 5-hydroxyindole-acetic acid (5HIAA), especially when there is
epletion of 5-HT [10].
Evidence show that the FST generated decreased in integrated
ptical density of TPH-positive regions [31] and this effect could
xplain the lower level of brain tryptophan. Although, we  found
ncrease levels of tryptophan in CSF with acute and concomitant
dministration of ﬂuoxetine and tryptophan, which may  indicate
n acute and transient effect of these two treatments. This neuro-
hemical effect in CSF tryptophan concentrations was  not found in
ryptophan and ﬂuoxetine administration singly (Fig. 4). Previous
tudies reported a signiﬁcant increase in the brain 5-HT synthe-
is [17,28] and increased expression of the enzyme THP2 [25] after
cute administration of this SSRI.
These ﬁndings suggest that a chronic treatment, using trypto-
han as a nutritional supplement, as well as the performance of
ehavioral tests, may  alter the expression or activity of the enzyme
-HTP, an essential step for the synthesis of 5-HT. It was not possible
o verify a beneﬁc effect tryptophan alone or even of concomitant
dministration of ﬂuoxetine and tryptophan in our study.
The possibility that other mechanisms may  be operating simul-
aneously for the effect shown in the experimental group, as a larger
[etters 499 (2011) 59– 63
increase in 5-HT enzymatic degradation by monoamine oxidase
cannot be ruled out. In this context, further studies are needed for
elucidate the mechanisms by which oral tryptophan in combina-
tion or not with ﬂuoxetine induced such effects.
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